Clinical Trial Update: Safety and Efficacy of GSK Neisseria Gonorrhoeae GMMA (NgG) Investigational Vaccine When Administered to Healthy Adults 18 to 50 Years of Age. [Phase 1, Phase 2]

View source ↗

Summary

GSK's NgG vaccine for Neisseria gonorrhoeae was evaluated for safety and preliminary efficacy in healthy adults aged 18 to 50 in Phase 1/2 trials. The studies h…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gonorrhea

Drugs mentioned

• NgG Gonorrhea Vaccine (NgG (Neisseria gonorrhoeae GMMA) vaccine)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Sexually Transmitted Diseases | Phase 1, Phase 2 | Status: COMPLETED